Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 7:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 77 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Gadolinium-DTPA Clear all
Withdrawn No phase listed Observational

QSM and Regional DCE MRI Permeability Using GOCART Technique

NCT03091803
View directory record Official record
Conditions
Intracranial Neoplasm
Interventions
Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Gadobenate Dimeglumine, Gadoterate Meglumine, Magnetic Resonance Imaging
Device · Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2021 · Synced Sep 8, 2026, 7:10 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis

NCT04879628
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
SAR441344 IV, placebo IV, SAR441344 SC, placebo SC, MRI contrast-enhancing preparations
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
4
States / cities
Phoenix, Arizona • Tampa, Florida • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 8, 2026, 7:10 PM EDT
Completed Not applicable Interventional

Identification of Adverse Plaque Characteristics by Coronary MR Angiography

NCT01986868
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Coronary MR Angiography (CMRA)
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Sep 8, 2026, 7:10 PM EDT
Withdrawn Not applicable Interventional

A Comparison of Indirect and Direct MR Arthrography of the Shoulder Using Arthroscopic Correlation

NCT01416740
View directory record Official record
Conditions
Shoulder Pain
Interventions
Indirect MRA of shoulder, Gadopentetate Dimeglumine
Procedure · Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 25, 2014 · Synced Sep 8, 2026, 7:10 PM EDT
Completed Phase 4 Interventional

A Study Comparing Two Magnetic Resonance Imaging (MRI) Contrast Agents in MRI of the Brain

NCT00323102
View directory record Official record
Conditions
Brain Pathology
Interventions
Multihance
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 22, 2008 · Synced Sep 8, 2026, 7:10 PM EDT
Completed No phase listed Observational

Gadolinium-Based-Contrast-Agents (GBCA) Enhancement During MR Urography

NCT03910114
View directory record Official record
Conditions
Magnetic Resonance Imaging Contrast Agents
Interventions
Magnevist, Dotarem, Gadovist
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Up to 21 Years
Enrollment
500 participants
Timeline
1990 – 2019
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Sep 8, 2026, 7:10 PM EDT
Completed Not applicable Interventional

MRI and CT Scans to Evaluate Invasive Cervical Cancer Before Treating Patients

NCT00004936
View directory record Official record
Conditions
Cervical Cancer
Interventions
iodinated contrast dye, computed tomography, magnetic resonance imaging, gadopentetate dimeglumine
Drug · Procedure · Radiation
Lead sponsor
American College of Radiology Imaging Network
Network
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
2
States / cities
Morristown, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 27, 2013 · Synced Sep 8, 2026, 7:10 PM EDT
Completed Not applicable Interventional

Novel MRI Techniques for the Characterization and Treatment Assessment of High Grade Brain Lesions

NCT04132843
View directory record Official record
Conditions
Brain Neoplasm, Lymphoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Malignant Brain Neoplasm
Interventions
Gadobenate Dimeglumine, Gadobutrol, Magnetic Resonance Imaging
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 20, 2022 · Synced Sep 8, 2026, 7:10 PM EDT
Terminated No phase listed Observational

Comparison of Contrast Agents for MRI Perfusion Analysis in Brain Tumor Patients

NCT02095353
View directory record Official record
Conditions
Central Nervous System Neoplasms
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Sep 8, 2026, 7:10 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Prolonged Gadolinium Retention After MRI Imaging

NCT02421029
View directory record Official record
Conditions
Heavy Metal Toxicity
Interventions
edetate calcium disodium
Drug
Lead sponsor
Mt. Sinai Medical Center, Miami
Other
Eligibility
20 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Miami Beach, Florida
Source: ClinicalTrials.gov public record
Updated Aug 28, 2017 · Synced Sep 8, 2026, 7:10 PM EDT
Terminated Phase 3 Interventional Results available

Magnetic Resonance Imaging of the Liver in Children 0-2 Months of Age With an Intravenous Injection of Eovist/Primovist Which is a Contrast Agent

NCT02084628
View directory record Official record
Conditions
Magnetic Resonance Imaging
Interventions
Gadoxetate disodium (Eovist/Primovist, BAY86-4873)
Drug
Lead sponsor
Bayer
Industry
Eligibility
Up to 2 Months
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Sep 8, 2026, 7:10 PM EDT
Completed Phase 4 Interventional Results available

Primovist / Eovist in Renally Impaired Patients

NCT00908596
View directory record Official record
Conditions
Contrast Media
Interventions
Gadoxetic acid disodium (Primovist, BAY86-4873)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
12
States / cities
Los Angeles, California • Jacksonville, Florida • Honolulu, Hawaii + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2015 · Synced Sep 8, 2026, 7:10 PM EDT
Withdrawn Phase 2 Interventional

PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer

NCT04910425
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Fluorine F 18 DCFPyL, Gadobenate Dimeglumine, Gadobutrol, Magnetic Resonance Imaging, Multiparametric Magnetic Resonance Imaging, Positron Emission Tomography, Transrectal Ultrasonography Guided Biopsy
Drug · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Sep 8, 2026, 7:10 PM EDT
Completed Phase 2 Interventional Results available

P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)

NCT02633501
View directory record Official record
Conditions
CNS Lesion, Blood Brain Barrier Defect
Interventions
P03277, Gadobenate dimeglumine, MRI
Drug · Device
Lead sponsor
Guerbet
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
10
States / cities
Chicago, Illinois • Boston, Massachusetts • Farmington Hills, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2021 · Synced Sep 8, 2026, 7:10 PM EDT
Completed Phase 4 Interventional Results available

Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction

NCT02597543
View directory record Official record
Conditions
Heart Transplant, Acute Graft Rejection, Chronic Graft Rejection
Interventions
Regadenoson, Gadolinium, Cardiac MRI
Drug · Procedure
Lead sponsor
Paul Kim
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Sep 8, 2026, 7:10 PM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

ASIS for GAMMAGARD in Primary Immunodeficiency

NCT02123615
View directory record Official record
Conditions
Primary Immunodeficiency
Interventions
Gadolinium For abdomen, Gadolinium For lower back, Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, Efficacy of Gammagard subcutaneously at Week 36, Efficacy of Gammagard subdermally at Week 36, Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, Adverse Reactions of Gammagard subcutaneously at Week 36, Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, Adverse Reactions of Gammagard subdermally at Week 36
Drug
Lead sponsor
ASIS Corporation
Industry
Eligibility
21 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Westminster, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2015 · Synced Sep 8, 2026, 7:10 PM EDT
Not listed Phase 3 Interventional

Comparative Effectiveness of Gadopiclenol for Evaluation of Adult Congenital Heart Anatomy and Hemodynamics

NCT06406517
View directory record Official record
Conditions
Congenital Heart Disease
Interventions
Gadopiclenol, Gadobenate dimeglumine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Sep 8, 2026, 7:10 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Efficacy of EVP 1001-1 (SeeMore) in the Assessment of Myocardial Viability in Patients With Cardiovascular Disease

NCT01989195
View directory record Official record
Conditions
ISCHEMIC CARDIOMYOPATHY
Interventions
'SEEMORE' - MANGANESE-ENHANCED MRI CONTRAST REAGENT
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 1, 2017 · Synced Sep 8, 2026, 7:10 PM EDT
Completed Phase 2 Interventional Results available

Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases

NCT00375830
View directory record Official record
Conditions
Cancer
Interventions
Bone scan, 99mTc-methyl diphosphonate, Positron Emission Tomography (PET) scan, 18F-Fludeoxyglucose (18F-FDG), Computed Tomography (CT) scan, 18F-Sodium Fluoride (18F-NaF), Whole Body Magnetic Resonance Imaging (WB-MRI) scan, Gadopentetate dimeglumine, Gadofosveset, Gadobutrol
Procedure · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Sep 8, 2026, 7:10 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Clinical Trial of Manganese-Enhanced MRI (MEMRI) to Assess Peri-Infarct Injury

NCT02933034
View directory record Official record
Conditions
ISCHEMIC CARDIOMYOPATHY
Interventions
Manganese-enhanced MRI contrast reagent, Gadolinium-enhanced MRI contrast reagent
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Sep 8, 2026, 7:10 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Comprehensive Evaluation of Ischemic Heart Disease Using MRI

NCT01234870
View directory record Official record
Conditions
Heart Disease, Ischemic, Atherosclerosis, Coronary
Interventions
Gadolinium, Adenosine
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Sep 8, 2026, 7:10 PM EDT
Terminated Not applicable Interventional Results available

Fludeoxyglucose F 18 Positron Emission Tomography and Magnetic Resonance Perfusion Imaging in Patients With Neurofibromatosis 1 and Plexiform Neurofibroma

NCT00060008
View directory record Official record
Conditions
Neurofibromatosis Type 1, Precancerous Condition
Interventions
fludeoxyglucose F 18, gadopentetate dimeglumine
Radiation
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 25 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 3, 2014 · Synced Sep 8, 2026, 7:10 PM EDT
Terminated Not applicable Interventional Results available

Transrectal MRI-Guided Biopsy in Identifying Cancer in Patients With Suspected Prostate Cancer

NCT02501759
View directory record Official record
Conditions
Health Status Unknown, Prostate Carcinoma
Interventions
3 Tesla Magnetic Resonance Imaging, Gadodiamide, Multiparametric Magnetic Resonance Imaging, Transrectal Biopsy, Ultrasound-Guided Prostate Biopsy
Procedure · Radiation
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Sep 8, 2026, 7:10 PM EDT
Completed Early Phase 1 Interventional

Topotecan Using Convection-Enhanced Delivery (CED) in High Grade Glioma

NCT02278510
View directory record Official record
Conditions
Malignant Glioma, WHO Grade III or IV Recurrent Glioma
Interventions
Topotecan, Gadolinium DTPA, Cleveland Multiport Catheter
Drug · Device
Lead sponsor
Michael Vogelbaum, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Sep 8, 2026, 7:10 PM EDT